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Abstract
Purpose To assess the reliability of CXR and to describe CXR findings and clinical and laboratory characteristics associ-
ated with positive and negative CXR.
Methods Retrospective two-center study on consecutive patients admitted to the emergency department of two north-western 
Italian hospitals in March 2020 with clinical suspicion of COVID-19 confirmed by RT-PCR and who underwent CXR within 
24 h of the swab execution. 260 patients (61% male, 62.8 ± 15.8 year) were enrolled. CXRs were rated as positive (CXR+) 
or negative (CXR−), and features reported included presence and distribution of airspace opacities, pleural effusion and 
reduction in lung volumes. Clinical and laboratory data were collected. Statistical analysis was performed with nonparametric 
tests, binary logistic regression (BLR) and ROC curve analysis.
Results Sensitivity of CXR was 61.1% (95%CI 55–67%) with a typical presence of bilateral (62.3%) airspace opacification, 
more often with a lower zone (88.7%) and peripheral (43.4%) distribution. At univariate analysis, several factors were found 
to differ significantly between CXR+ and CXR−. The BLR confirmed as significant predictors only lactate dehydrogenase 
(LDH), C-reactive protein (CRP) and interval between the onset of symptoms and the execution of CXR. The ROC curve 
procedure determined that CRX+ was associated with LDH > 500 UI/L (AUC = 0.878), CRP > 30 mg/L (AUC = 0.830) and 
interval between the onset of symptoms and the execution of CXR > 4 days (AUC = 0.75). The presence of two out of three 
of the above-mentioned predictors resulted in CXR+ in 92.5% of cases, whereas their absence in 7.4%.
Conclusion CXR has a low sensitivity. LDH, CRP and interval between the onset of symptoms and the execution of CXR 
are major predictors for a positive CXR.
Keywords Chest X-ray · Coronavirus disease 2019 (COVID-19) · Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) · Real-time reverse transcriptase-polymerase reaction chain test (RT-PCR) · Laboratory test · Sensitivity
Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
Medical symptoms vary from asymptomatic inflamma-
tion to a wide variety of systemic and/or respiratory mani-
festations [1]. Laboratory findings among hospitalized 
COVID-19 patients include lymphopenia, high levels of 
aminotransaminase and elevated inflammatory markers [2]. 
The SARS-CoV-2 diagnostic test is the real-time reverse 
transcriptase-polymerase reaction chain test (RT-PCR), 
which is very specific but has low sensitivity (54–73%) [3].
Regarding imaging, computed tomography (CT) presents 
a sensitivity up to 95%, vastly outperforming RT-PCR [4]. 
However, the Multinational Consensus Statement from the 
Fleischner Society stated that CT scan should not be used for 
screening or as a first-line test for the diagnosis of COVID-
19 [5], also because the use of a non-dedicated scanner CT 
requires time-consuming and laborious decontamination 
procedures to limit the risk of cross infection [6]. In this 
light, chest X-rays (CXR) can be considered as an alternative 
to CT, also for the easy and fast cleaning of the equipment 
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and the large availability of portable units. In Northern Italy, 
the epicenter of the Italian SARS-CoV-2 pandemic, some 
emergency departments use CXR as the first line of triage 
in patients with suspected COVID-19 also because of the 
relatively long waiting time for RT-PCR. Although, the com-
mon opinion is that CXR may not be sufficiently sensitive 
for the detection of COVID-19 lung disease especially in the 
early stages of the pathology, there are only a few studies in 
the literature assessing its sensitivity in respect to the current 
diagnostic gold standard, RT-PCR [7–12]. Furthermore, no 
pertinent information is available concerning the association 
of CXR findings with clinical and laboratory data.
We considered the issue worth of further exploration 
and planned a study aimed to assess the reliability of CXR 
compared to RT-PCR in symptomatic patients with positive 
COVID-19 confirmed by RT-PCR. The secondary aim was 
to describe CXR findings in the context of demographics 
characteristics, comorbidities, and clinical/laboratory char-
acteristics associated with positive and negative CXR.
Materials and methods
Study design and population
The study was piloted in agreement with the 1964 Helsinki 
declaration and its later amendments, was approved by the 
institutional review board. The requirement for informed 
patient consent was waived.
This was a retrospective two center study on consecutive 
patients who were admitted to the emergency department 
of two Northern Italy hospitals between 1 and March 31, 
2020 with clinical suspicion of COVID-19 confirmed by 
RT-PCR, and who underwent CXR within 24 h of the swab 
execution (Fig. 1).
Clinical and laboratory data
The demographic data, comorbidities, clinical and labo-
ratory data of the patients were collected in accordance 
with the structured report released by the “Società Italiana 
di Radiologia Medica e Interventistica (SIRM)” [13]. As 
for comorbidities, variables included in the analysis were: 
presence of cardiac disease, diabetes, obesity, hypertension, 
smoke history, ACEi/Sartan or FANS therapy. As for clini-
cal data: Fever, Cough, Rhinitis, Dyspnea, Pharyngodynia, 
Myalgias, Asthenia, Conjunctivitis, Headache, Nausea, 
Vomit and Diarrhea.
Regarding Laboratory data: white blood cells (WBC) 
count, C-reactive protein (CRP), Lactate dehydrogenase 
(LDH), hepatic enzymes, creatin kinase (CK), blood’s pH 
and arterial partial pressure of carbon dioxide (PaCO2). RT-
PCR protocol: extraction with  QIAsymphony® DSP Virus/
Pathogen Midi Kit, amplification with Seegene AllplexTM 
2019-nCoV Assay (target genes E, N, RdRP).
Image acquisition and analysis
CXRs were acquired as computed or digital radiographs 
according to the local protocols. All CXR studies were 
analyzed by two observers (MC and MG with more than 
5 years’ experience) using a picture archiving and com-
munication system (PACS) workstation [Carestream Vue 
PACS v11.3.4 (Carestream Health, Inc, Rochester, NY)]. In 
the few cases of disagreement, the decision was reached by 
consultation with a senior radiologist (RF with more than 
10 years’ experience). CXRs were rated as positive/negative, 
and the features reported included presence and distribution 
of airspace opacities, pleural effusion and reduction in lung 
volumes [7].
Fig. 1  Study flow chart
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Statistical analysis
Continuous variables were tested for normality with the 
Shapiro-Wilks W test. When normal, they were expressed 
as mean and standard deviation; otherwise, as median with 
first (Q1) and third (Q3) quartile. Categorical variables were 
presented as absolute numbers and percentages.
The univariate analysis used nonparametric tests: for 2 
independent continuous variables the Mann–Whitney test, 
for categorical variables the χ2 test (with Yates’s correction 
for 2 × 2 tables) or Fisher’s exact test. Binary logistic regres-
sion (BLR) was run on variables determined as significant 
by the univariate analysis.
Continuous variables with significant differences were 
dichotomized by the ROC curve procedure to derive the 
regions with the strongest association with CXR+. The 
thresholds were obtained through three methods: maximiza-
tion of the harmonic mean of Sensitivity and Specificity and 
of Youden’s index and minimization of the distance from the 
upper left corner. Agreement between the three indications 
was required.
Significant association with CXR+ corresponded to 
p < 0.05 and 95% CI of ORs totally above 1. The analy-
sis was run on StatPlus: Mac v.7 (AnalysisSoft.Walnut.
CA.USA).
Results
The baseline characteristics of the study population are listed 
in Table 1.
Using RT-PCR as gold standard, the sensitivity of CXR 
was 61.1% (95%CI 55–67%). The airspace opacities found 
at CRX were most commonly distributed in peripheral 
(69/159 = 43.4%) and lower zone (141/159, 88.7%) and most 
of the patients had bilateral involvement (99/159, 62.3%). 
Pleural effusion was found in 17 cases (10.7%) and lung 
volume reduction in 12 cases (7.5%). The CXR findings are 
summarized in Table 2.
The study sample of 260 patients with COVID-19 con-
firmed by RT-PCR were subdivided in two groups: 159 
patients with positive CXR (CXR+) and 101 patients nega-
tive CXR (CXR−). Patients in the CXR+ group were older 
than in the CXR− one (66.5 ± 14.0 vs. 56.7 ± 15.5 years; 
p < 0.001), while there was an overlapping gender distribu-
tion (64.2% vs. 56.4% of male; p = 0.27).
The results of the univariate analysis on comorbidity, 
clinical and laboratory data of the two groups are listed and 
reported in Table 3. Several factors were found to differ sig-
nificantly between CXR+ and CXR−. Regarding comorbidi-
ties, the presence of hypertension (p = 0.0002) and a concur-
rent treatment with sartans (p = 0.03) were more frequent in 
CXR+. Among clinical data, dyspnea (p = 0.01), myalgia 
(p = 0.004) and a longer interval between the onset of symp-
toms and the execution of CXR (p = 0.0002) were typical of 
CXR+. With regard to laboratory data, the presence of lym-
phopenia (p = 0.005), high level of CRP (p < 0.0001), LDH 
(p < 0.0001), hepatic enzymes (p = 0.0009) or CK (p = 0.02), 
 PaCO2 (p = 0.02) and a reduction in blood’s pH (p = 0.04) 
were more common in CRX+.
The significant differences exhibited by the continu-
ous variables LDH, CRP and interval between the onset of 
symptoms and the execution of CXR suggested a potential 
predictive role for them. The ROC curve procedure (Table 4 
Table 1  Baseline characteristics of the study population (N = 260)
Demographic characteristics
Age (years) 62.8 ± 15.8
Males 61.0%


























WBC count  (109/L) 6.2 (4.9–8.5)
Lymphocytes (%) 19.3%
Lymphocytes (number) 1.1 (0.8–1.5)
CRP value (mg/L) 37.7 (8.3–106.9)
LDH value (UI/L) 517 (390–669)
Alteration hepatic values 18.0%
CK elevation 19.0%
pH 7.46 (7.43–7.49)
PaCO2 (mmHg) 34 (30–37)
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and Fig. 2) identified as the threshold for CRX+ the range 
LDH > 500 UI/L, CRP > 30 mg/L and the interval between 
the onset of symptoms and the execution of CXR, days > 4. 
The BLR applied to the dichotomized variables confirmed 
their significant value as prognostic role (Table 5).
The presence at the CXR of all three predictors was asso-
ciated to a positive CXR in 95.3% of cases, the presence of 
two of them to 89.2%, of one to 40.7%, and their absence to 
7.4%. The presence of at least two of the above-mentioned 
characteristics resulted in CXR+ in 92.5% of cases. Figure 3 
illustrates the 95%CI for the Odds Ratios for positive CXR 
in presence of all 3 prognostic favors, of 2, of 1 and of none. 
In patients with both LDH > 500 and CRP > 30, in 74% of 
cases, at least 4 days had elapsed since the onset of symp-
toms. Figure 4 illustrates two cases without (A and B) and 
two with (C and D) predictor factors (Table 6).
Discussion
Our study investigated the role of CXR in patients with 
COVID-19 and its association with clinical and laboratory 
data. The main findings may be summarized as follow:
• CXR when compared with RT-PCR has a sensitivity 
of 61% (95%CI 55–67%) and, when positive, it usually 
shows the presence of bilateral airspace opacities with 
peripheral distribution and predominant involvement of 
the lower lobes.
• Several clinical and laboratory data are associated with 
the outcome of CXR. The most significant ones LDH and 
CRP time interval between the onset of symptoms and 
the CXR.
To the best of our knowledge, there are only seven papers 
in the literature, excluding case reports and case series, 
evaluating the sensitivity of CXR in COVID-19 patients. 
Table 4 compares our results on sensitivity of CXR with 
those of the authors who performed similar estimates [7–12]. 
We found a sensitivity of CXR of 61.1% (95%CI 55–67%) 
in the identification of abnormalities in COVID-19 patients. 
Five studies, including ours, yield consistent 95%Confidence 
Intervals [7, 9–11]. There are two exceptions, at the two 
ends of the spectrum of values: the lower value reported by 
Weinstock et al. [8], relative to patients admitted to urgent 
care centers, therefore likely to have a lower grade pathol-
ogy, and the higher value reported by Schiaffano et al. [12] 
for patients hospitalized in the Lombardy region, which 
might be due to the higher-grade pathology present in that 
region. Overall, the CXR is characterized by relatively low 
sensitivity in the identification of pulmonary alterations of 
COVID-19.
As for radiological findings, according to recent literature 
data, our study described a scenario superimposable on the 
one described for CT with the presence of peripherally dis-
tributed, bilateral opacity with prevalence in the lower lobes 
[14, 15] and low incidence of pleural effusion.
Regarding relationship with clinical symptoms both uni-
variate and multivariate analysis of our sample of patients 
underlined a significant difference between CXR+ and 
CXR- in the time elapsed between the onset of symptoms 
and the execution of CXR; in particular patients who had a 
negative result performed CXR at a median of 4 days after 
the onset of symptoms, about 3 days sooner than the patients 
with positive CXR.
The COVID-19 patients are known to have a dynamic 
radiological pattern which varies with their clinical evolu-
tion. Four stages of lung involvement were defined for CT 
[14]: (1) early stage (0–4 days after initial symptoms), with 
ground glass opacity (GGO) representing the main radio-
logical demonstration; (2) progressive stage (5–8 days after 
the onset of symptoms), with a worsening of pulmonary 
involvement and presence of diffuse GGO, crazy-paving 
pattern and consolidation; (3) peak stage (9–13 days after 
the onset of symptom) with prevailing dense consolidation 
is prevalent in association with other findings; (4) absorption 
stage (≥ 14 days after the onset of the initial symptoms) in 
which the consolidation is gradually absorbed and no crazy-
paving pattern is present.
Wong et al. [7] reported that also the findings at CXR 
changed over time, reaching the peak stage at 10–12 days 
from the onset of symptoms. This means that our CXR- 
patients, who had a median interval of 4(1–7) days between 
initial symptoms and CRX, were in the “early stage” of 
the disease, characterized by the presence of GGO, which 
may be extremely difficult to detect on CXR [16]. Our data 
emphasizes the concept that particularly in the early stages 
of the disease, CXR has a low sensitivity for COVID-19. 
However, this clinical-radiological delay may also be useful 
Table 2  CXR findings
Findings of 159 CXR+ Number %
Distribution at CXR
Peripheral predominant 69 43.4
Perihilar predominant 34 21.4
Neither peripheral nor perihilar 56 35.2
Bilateral lungs 99 62.3
Upper zone involvement 37 23.3
Middle zone involvement 110 69.2
Lower zone involvement 141 88.7
No zonal predominance 32 20.1
Other features at CXR
Pleural effusion 17 10.7
Reduction in lung volumes 12 7
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Table 3  Comorbidity, clinical 
and laboratory data of CXR+ 
versus CXR−
Significant differences were reported in italics
Comorbidity CXR+ (n = 159) CXR− (n = 101) p value
Cardiac disease 23.8% 16.1% 0.19
Hypertension 54.7% 29.8% 0.0002
Diabetes 13.7% 8.3% 0.28
Obesity 12.1% 5.4% 0.11
Smoke history 7.8% 10.8% 0.47
Oncologic history 17.8% 11.7% 0.27
FANS 3.9% 2.5% 0.71
ACEi 11.9% 8.5% 0.5
Sartans 24.1% 10.6% 0.03
Clinical data
Onset of symptoms—CXR (days) 7 (4–8) 4 (1–7) 0.0002
Fever 92.3% 88.0% 0.35
Cough 61.3% 73.3% 0.06
Rhinitis 2.6% 3.0% 0.99
Dyspnea 42.9% 27.0% 0.01
Pharyngodynia 65% 14.0% 0.05
Myalgias 6.5% 18.0% 0.004
Asthenia 12.3% 14.0% 0.71
Conjunctivitis 0% 3.0% 0.06
Headache 3.2% 9.0% 0.05
Nausea 4.5% 4.0% 0.99
Vomit 2.6% 4.0% 0.72
Diarrhea 14.2% 16.0% 0.72
Laboratory data
Lymphopenia 48.3% 27.1% 0.005
WBC count  (109/L) 6.11 (4.87–8.49) 6.2 (4.9–8.5) 0.99
Lymphocytosis 1.7% 3.0% 0.62
Lymphocytes (%) 15.3% 22.5% 0.002
Lymphocytes (number) 0.98 (0.74–1.29) 1.30 (0.88–1.85) 0.0002
CRP Elevation 93.70% 56.6% < 0.0001
CRP (mg/L) 77.0 (27.8–128.8) 8.1 (2.4–23.6) < 0.0001
LDH elevation 83.2% 28.6% < 0.0001
LDH value (UI/L) 599 (511–839) 277 (319–461) < 0.0001
Alteration hepatic values 25.4% 6.6% 0.0009
CK elevation 24.6% 10% 0.02
pH 7.47 (7.44–7.50) 7.4 5 (7.43–7.47) 0.04
PaCO2 (mmHg) 32.5 (30–36) 36 (33–3) 0.02
Table 4  ROC curves procedure 
for the discriminating ability 
of LDH, CRP and the interval 
between the onset of symptoms 
and the execution of CXR
AUC area under the curve, SNS sensitivity, SPC specificity, PPV positive predictive value, NVP negative 
predictive value, DA diagnostic accuracy
Variable AUC Youden’s index Threshold SNS SPC PPV NPV DA
LDH 0.88 0.67 > 500 UI/L 0.77 0.90 0.93 0.69 0.81




0.75 0.41 > 4 days 0.76 0.65 0.77 0.64 0.72
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to address a differential diagnosis with “classical” commu-
nity-acquired pneumonia, in which the alterations become 
manifest in the CXR within a time interval of 12 h from the 
beginning of the symptomatology [17].
Regarding laboratory data, a marked reduction in lym-
phocytes and elevation of the concentrations of CRP, LDH 
and hepatic enzyme are often observed in COVID-19 
patients. Recently, a few laboratory features were reported 
to be associated with severe disease in COVID-19 patients 
[1, 9, 18, 19]. In a study of more than 1000 patients, Guan 
et al. [9] showed that among the laboratory parameters that 
assessed inflammation and cell damage, CRP and LDH were 
significantly higher in patients with a severe disease than in 
patients with a non-severe disease and thus appeared to have 
a prognostic impact.
A recent study [19] found that LDH can be recognized as 
an important predictive factor for severe COVID-19 mani-
festations. It must be emphasized that during the 2009 influ-
enza A (H1N1) pandemic, 77.8% of patients whose labora-
tory data indicated elevation of LDH, had lung involvement, 
suggesting that LDH elevation was associated with multiple 
pathogenic factors including viruses, and was important to 
lung injury [20]. In addition, Henry et al. [19] recently dem-
onstrated that elevated LDH values were associated with 
the risk of developing severe disease (sixfold increase) and 
mortality (16-fold increase).
CRP level significantly increases in COVID-19 patients 
due to inflammatory reaction and tissue destruction. High 
concentrations of CRP were reported to indicate more severe 
illness-, associated with lung damage and worse prognosis 
[21, 22]. In addition, CRP values in other viral diseases, such 
as H1N1 influenza, were higher for patients with a serious 
history of the disease [23].
According to our results, LDH and CRP are major predic-
tors of a positive CXR: in presence of both values above the 
respective threshold of 30 mg/L and 500 U/L respectively, 
the CXR is positive in about 90% of the patients. This is 
also in line with the findings of Guan et al. [9] on the higher 
frequency of positive CXR in patients with a more severe 
disease.
The overall scenario of our findings suggests that base-
line CXR, when integrated with laboratory evaluations, can 
have a role in the identification of patients with more severe 
involvement of the pathology. This integrated approach may 
be a valid alternative when or where other more specific tests 
(in primis RT-PCR tests) are limited. To this end, an added 
value comes from the promising artificial intelligence tech-
niques developed for improving the diagnostic accuracy of 
imaging and assisting radiologists and clinicians in the CXR 
evaluation as part of the COVID-19 triage process [24]. The 
results of our study should also warn that when dealing with 
the suspicion of a positive COVID-19 in a patient admit-
ted to the emergency room a few days after the onset of 
symptoms and without severe alterations of CRP and LDH, 
physicians should not be surprised to be faced with a nega-
tive CXR.
This study has some limitations. First, it is a retrospec-
tive study on a limited number of patients, even if it is one 
of largest in the literature dealing with sensitivity of CXR. 
Second, we only assessed the sensitivity of the CXR without 
evaluating its specificity and predictive values by comparing 
Fig. 2  ROC curves for the discriminating ability of lactate dehydro-
genase (LDH) AUC = 0.88; C-reactive protein (CRP), AUC = 0.83; 
and Number of days (days) between the onset of symptoms and the 
execution of CXR, AUC = 0.75
Table 5  BLR applied to the dichotomized variables
LCL lower control limit; UCL upper control limit
Variable p value Odds ratio LCL UCL
LDH > 500 UI/L 0.0001 11.0 3.2 36.0
CRP > 30 mg/L 0.0006 8.0 2.5 27.0
Interval symptoms—
execution CXR > 4
< 0.0001 4.0 1.3 12.5
Fig. 3  Odds Ratio 95%CIs of the three predictors for agreement 
of CXR with RT-PCR. 95%CIs completely above 1 correspond to 
positive effect on CXR+; completely below 1 correspond to adverse 
effects; including 1 to randomity
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it to a non-COVID-19 control group. Third, we did not cor-
related the outcome of CXR with the clinical outcome and 
this should be the goal of further prospective studies that 
effectively assess the additional role of CXR in patients with 
suspected SARS-CoV-2 infection.
In conclusion, the baseline CXR performed on 260 
patients with COVID-19 confirmed by RT-PCR has a 
sensitivity of 61.1% with a typical presence of bilateral 
airspace opacification more often with a lower zone and 
peripheral distribution. Among demographic characteris-
tic, comorbidities, clinical and laboratory data, LDH > 500 
U/L and CRP > 30 mg/L and an interval between the onset 
of symptoms and the execution of CXR of more than 4 days 
are the major predictors for a positive CXR.
Fig. 4  Baseline chest X-ray finding in COVID-19 patients associated 
with clinical and laboratory data. a 47-year-old man, without comor-
bidities, presented with fever, cough, rhinitis and conjunctivitis for 
3 days. Laboratory test: Lymphocytes 1.31  (109/L), CRP = 8.3 mg/L 
and LDH = 330 UI/L. The chest X-ray resulted negative. b 46-year-
old man, without comorbidities, presented with fever, cough, and 
Pharyngodynia for 1 days. Laboratory test: Lymphocytes 0.8  (109/L), 
CRP = 3 mg/L and LDH = 346 UI/L. The chest X-ray resulted nega-
tive. c 58-year-old man, without comorbidities, presented with fever 
and cough for 7  days. Laboratory test: Lymphocytes 0.67  (109/L), 
CRP = 141.9  mg/L and LDH = 711 UI/L. The chest X-ray resulted 
positive with peripheral airspace opacification in the left lower lobe. 
D: 55-year-old woman, without comorbidities, presented with fever 
and cough for 7  days. Laboratory test: Lymphocytes 1.13  (109/L), 
CRP = 60.9 mg/L and LDH = 784 UI/L. The chest X-ray resulted pos-
itive with neither peripheral nor perihilar airspace opacification with 
middle and lower zone involvement
 La radiologia medica
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